Cindy Parks Thomas

TL;DR: Average annual growth rates for the prescription of psychotropics to adolescents increased from 1994 to 2001, with especially rapid acceleration after 1999, which may be associated with changing thresholds of diagnosis and treatment, availability of new medications, and changes in federal regulatory policies concerning promotion of medications by the pharmaceutical industry.

TL;DR: MMT in pregnancy was associated with improved maternal and fetal outcomes, and rates of neonatal abstinence syndrome were similar for mothers receiving different doses, so MMT should be a covered service available to all individuals.

TL;DR: Clinicians were most likely to adopt naltrexone if they were affiliated with treatment programs that actively promoted its use, and information about it must be properly directed, clinicians must be convinced of its effectiveness, and the treatment organizations in which clinicians work must promote its use.

TL;DR: Buprenorphine maintenance treatment is associated with improved outcomes compared with placebo for individuals and pregnant women with opioid use disorders and should be considered for inclusion as a covered benefit.

TL;DR: 11 years of Massachusetts PMP data are analyzed to evaluate trends in opioid prescribing, dispensing, and usage.